Pembrolizumab
Brand Name: Keytruda
Manufacturer: Merck Canada Inc.
Indication
Indication
First-line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colorectal cancer (mCRC).
Specific CRC Subtype: MSI-H/dMMR
Stage: IV
Therapy Line: First-line
Health Canada Approval: Approved
pCPA Negotiation Status: Completed
Reimbursed in: AB (Alberta), BC (British Columbia), MB (Manitoba), NB (New Brunswick), NL (Newfoundland and Labrador), NS (Nova Scotia), ON (Ontario), PEI (Prince Edward Island), QC (Quebec), SK (Saskatchewan)
New Search
